vitiligo
VITILIGO
Vitiligo is an acquired, often familial, melanocytopenic disorder that produces focal depigmentation of the skin.
About half of the patients has onset of lesion before the age of 20.
It is a progressive disease wherein spontaneous repigmentation may occur within 6 months.
Precipitating factors include emotional stress, sunburn, chemical exposure, skin trauma, inflammation, irritation or rash that may precede the lesions by 2-3 months.
Lesions are white-colored macules or patches with well-defined borders and otherwise normal skin surface.

Patient Education

  • Educate patient, friends & relatives about the disease
    • It is important for them to overcome any stigmas they may have about vitiligo
  • Explain the nature of the disease to the patient
    • Vitiligo does not effect the patient’s health directly, but is a cosmetic issue
    • Spontaneous recovery may occur
  • Treatment options should be discussed
    • Treatment may be long & difficult, & the results are often unpredictable
    • Review the risks vs benefits along w/ expected outcomes of the treatment options
Editor's Recommendations
Most Read Articles
21 Apr 2020
A bidirectional association exists between alopecia areata (AA) and major depressive disorder (MDD) among probands and unaffected siblings, reveals a study. This suggests that shared familial mechanisms tend to cause AA and MDD.
16 Feb 2020
A 1.5% ruxolitinib cream does not seem to be effective for patients with alopecia areata, a recent phase II study has found.
17 May 2020
Treatment with serlopitant helps lessen pruritus associated with mild-to-moderate psoriasis, results of a phase II trial have shown. This supports the continued development of serlopitant for this condition.
Roshini Claire Anthony, 18 May 2020

Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).